Valuation : Norda ASA

Market Cap 51Cr 5.49Cr 4.73Cr 4.44Cr 4.05Cr 7.61Cr 522.46Cr 7.67Cr 53Cr 20Cr 264.93Cr 21Cr 20Cr 877.22Cr P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 26Cr 2.83Cr 2.44Cr 2.29Cr 2.09Cr 3.92Cr 269.14Cr 3.95Cr 27Cr 11Cr 136.48Cr 11Cr 10Cr 451.88Cr EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day-1.62%
1 week-1.62%
Current month-1.62%
1 month-1.62%
3 months-1.62%
6 months-0.12%
Current year-15.00%
1 week 85
Extreme 85
85
1 month 85
Extreme 85
85
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-1.62%+4.94%+107.32% 4.65Cr
-1.23%-1.91%+0.98%+17.94% 5.05TCr
-0.78%-3.33%+417.43%+502.12% 4.46TCr
-0.13%+0.60%+42.48%+17.59% 4.31TCr
-2.02%-3.34%+8.29%+73.24% 4.17TCr
-0.94%-1.77%+18.34%+46.84% 3.32TCr
-1.13%-4.30%+25.35%+119.54% 1.68TCr
+6.19%+4.49% - - 1.63TCr
+0.25%-0.41%+11.91%+29.03% 1.46TCr
-0.93%-3.25%+79.14%+39.67% 1.39TCr
Average -0.22%-1.11%+67.65%+105.92% 2.75TCr
Weighted average by Cap. -0.49%-1.05%+89.56%+122.44%

Financials

2023 2024
Net sales 8.69Cr 93.01L 80.08L 75.19L 68.64L 1.29Cr 88Cr 1.3Cr 8.91Cr 3.47Cr 45Cr 3.49Cr 3.42Cr 148.58Cr 37Cr 3.98Cr 3.43Cr 3.22Cr 2.94Cr 5.52Cr 378.58Cr 5.56Cr 38Cr 15Cr 191.97Cr 15Cr 15Cr 635.65Cr
Net income 3.12Cr 33.36L 28.72L 26.97L 24.62L 46.24L 32Cr 46.57L 3.2Cr 1.24Cr 16Cr 1.25Cr 1.23Cr 53Cr 13Cr 1.35Cr 1.16Cr 1.09Cr 99.45L 1.87Cr 128.23Cr 1.88Cr 13Cr 5.02Cr 65Cr 5.06Cr 4.95Cr 215.29Cr
Net Debt -31Cr -3.33Cr -2.87Cr -2.69Cr -2.46Cr -4.62Cr -316.88Cr -4.65Cr -32Cr -12Cr -160.68Cr -13Cr -12Cr -532.04Cr -25Cr -2.66Cr -2.29Cr -2.15Cr -1.96Cr -3.69Cr -253.32Cr -3.72Cr -26Cr -9.92Cr -128.46Cr -10Cr -9.78Cr -425.33Cr
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. NORD Stock